{
    "name": "obinutuzumab",
    "comment": "Rx",
    "other_names": [
        "Gazyva"
    ],
    "classes": [
        "Antineoplastics",
        "Anti-CD20 Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/gazyva-obinutuzumab-999895",
    "pregnancy": {
        "common": [
            "There are no data with obinutuzumab use in pregnant women to inform a drug-associated risk",
            "Based on findings from animal studies and the drug’s mechanism of action, obinutuzumab may cause fetal B-cell depletion",
            "Avoid administering live vaccines to neonates and infants exposed to obinutuzumab in utero until B-cell recovery occurs",
            "In animal reproduction studies, weekly IV administration of obinutuzumab to pregnant cynomolgus monkeys from day 20 of pregnancy until parturition which includes the period of organogenesis at doses with exposures up to 2.4 times the exposure at the clinical dose of 1000 mg monthly produced opportunistic infections and immune complex mediated hypersensitivity reactions",
            "Drug can cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 6 months after last dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk; because of potential of serious adverse reactions in breastfed child, advise women not to breastfeed during treatment and for 6 months after last dose",
            "Excreted in the milk of lactating cynomolgus monkeys and human IgG is known to be excreted in human milk; consider developmental and health benefits along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Progressive multifocal leukoencephalopathy (PML) including fatal PML, can occur in patients receiving obinutuzumab"
            ],
            "specific": [
                {
                    "type": "Hepatitis B virus reactivation",
                    "description": [
                        "Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies",
                        "Screen all patients for HBV infection before treatment initiation",
                        "Monitor HBV positive patients during and after treatment",
                        "Discontinue obinutuzumab and concomitant medications in the event of HBV reactivation"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anticipate tumor lysis syndrome; premedicate with anti-hyperuricemics and adequate hydration especially for patients with high tumor burden and/or high circulating lymphocyte count; correct electrolyte abnormalities, provide supportive care, and monitor renal function and fluid balance",
                "May reactivate hepatitis B virus (see Black Box Warnings)",
                "Progressive multifocal leukoencephalopathy (PML) reported (see Black Box Warnings)",
                "Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, and/or hyperphosphatemia from tumor lysis syndrome (TLS) can occur within 12-24 hr after the first infusion (see Premedication)",
                "Serious bacterial, fungal, and new or reactivated viral infections can occur; do not give obinutuzumab with an active infection",
                "Neutropenia may occur (in combination with chlorambucil, Grade 3 or 4 neutropenia reported in 34% of patients); patients with neutropenia are strongly recommended to receive antimicrobial prophylaxis throughout the treatment period; antiviral and antifungal prophylaxis should be considered",
                "Safety and efficacy of immunization with live or attenuated viral vaccines during or following obinutuzumab therapy have not been studied; immunization with live virus vaccines is not recommended during treatment and until B-cell recovery",
                "Hypersensitivity reactions have been reported; signs of immediate onset hypersensitivity (eg, dyspnea, bronchospasm, hypotension, urticaria, and tachycardia); late-onset hypersensitivity diagnosed as serum sickness have also been reported, symptoms (eg, chest pain, diffuse arthralgia and fever)"
            ],
            "specific": [
                {
                    "type": "Thrombocytopenia",
                    "description": [
                        "Thrombocytopenia may occur (in combination with chlorambucil, Grade 3 or 4 neutropenia reported in 12% of patients); in patients with Grade 3 or 4 thrombocytopenia, monitor platelet counts more frequently until resolution and consider dose delays of this drug and chemotherapy or dose reductions of chemotherapy",
                        "Monitor all patients frequently for thrombocytopenia and hemorrhagic events, especially during the first cycle; if clinically indicated, evaluate laboratory coagulation parameters",
                        "Transfusion of blood products (eg, platelet transfusion) may be necessary; consider withholding concomitant medications that may increase bleeding risk (platelet inhibitors, anticoagulants), especially during the first cycle"
                    ]
                },
                {
                    "type": "Disseminated intravascular coagulation (DIC)",
                    "description": [
                        "Fatal and severe DIC reported",
                        "If DIC is suspected, evaluate potential causes, and monitor coagulation parameters, platelet counts, and for signs and symptoms of bleeding or thrombosis",
                        "Manage according to standard guidelines for DIC",
                        "Supportive care, including transfusion of blood products and other medical management, may be necessary"
                    ]
                },
                {
                    "type": "Infusion-related reactions",
                    "description": [
                        "May cause severe and life-threatening infusion reactions (see Dosage Modification and Premedication sections)",
                        "Patients with pre-existing cardiac or pulmonary conditions are at greater risk of severe reactions",
                        "Monitor closely throughout the infusion and the post-infusion period; interrupt or discontinue infusion for reactions",
                        "Due to the risk of infusion induced hypotension, consider withholding antihypertensive treatments for 12 hr prior to, during , and for the first hour after administration until blood pressure is stable",
                        "Consider the benefits versus the risks of withholding their antihypertensive medication in patients who are at increased of hypertensive crisis"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "obinutuzumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "obinutuzumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "obinutuzumab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, obinutuzumab.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "obinutuzumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "obinutuzumab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of obinutuzumab by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, obinutuzumab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "obinutuzumab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and obinutuzumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Each drug is an anti-CD20 monoclonal antibody indicated for multiple sclerosis. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "obinutuzumab decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, obinutuzumab.\nEither decreases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Hypotension may occur during administration. Consider withholding antihypertensive treatments for 12 hr before and during each obinutuzumab infusion and for the first hour after administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "obinutuzumab decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "obinutuzumab increases effects of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Obinutuzumab may enhance the hypotensive effect of blood pressure lowering agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "obinutuzumab, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "chlorambucil increases toxicity of obinutuzumab by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Reported to cause thrombocytopenia and subsequent hemorrhage that may require blood product support."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "obinutuzumab, cholera vaccine. immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "obinutuzumab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and obinutuzumab both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of obinutuzumab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haemophilus influenzae type b vaccine",
            "description": {
                "common": "obinutuzumab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response may be suboptimal. Patients on chemotherapy with anti-B cell antibodies should wait =6 months after therapy before being vaccinated with inactivated vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "obinutuzumab decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "obinutuzumab decreases effects of measles (rubeola) vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "obinutuzumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "obinutuzumab decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, obinutuzumab.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "poliovirus vaccine inactivated",
            "description": {
                "common": "obinutuzumab decreases effects of poliovirus vaccine inactivated by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response may be suboptimal. Patients on chemotherapy with anti-B cell antibodies should wait =6 months after therapy before being vaccinated with inactivated vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "obinutuzumab decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "obinutuzumab decreases effects of rubella vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and obinutuzumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "obinutuzumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, obinutuzumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, obinutuzumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "typhoid polysaccharide vaccine",
            "description": {
                "common": "obinutuzumab decreases effects of typhoid polysaccharide vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "obinutuzumab decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "obinutuzumab decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "obinutuzumab increases effects of warfarin by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "obinutuzumab decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "obinutuzumab decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunization with live virus vaccines is not recommended during obinutuzumab treatment and until after B-cell recovery."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "obinutuzumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infusion related reactions",
            "percent": "69"
        },
        {
            "name": "Neutropenia",
            "percent": "33"
        },
        {
            "name": "Hypocalcemia",
            "percent": "32"
        },
        {
            "name": "Hyperkalemia",
            "percent": "31"
        },
        {
            "name": "Hyponatremia",
            "percent": "29"
        },
        {
            "name": "Creatinine increased",
            "percent": "28"
        },
        {
            "name": "AST",
            "percent": "28"
        },
        {
            "name": "SGOT increased",
            "percent": "25"
        },
        {
            "name": "AST",
            "percent": "16"
        },
        {
            "name": "SGPT increased",
            "percent": "16"
        },
        {
            "name": "Hypoalbuminemia",
            "percent": "15"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "13"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "12"
        },
        {
            "name": "Hypokalemia",
            "percent": "10"
        },
        {
            "name": "Anemia",
            "percent": "10"
        },
        {
            "name": "Pyrexia",
            "percent": "7"
        },
        {
            "name": "Cough",
            "percent": "2"
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Tumor lysis syndrome",
            "percent": null
        },
        {
            "name": "Hypophosphatemia",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Serum sickness",
            "percent": null
        },
        {
            "name": "Chronic lymphocytic leukemia",
            "percent": null
        }
    ]
}